Novel Assay Promises More Efficient Screening for Carriers of Fragile X Syndrome

Researchers have developed an innovative new nanopore sequencing assay to identify carriers of fragile X syndrome (FXS), the leading cause of monogenic autism spectrum disorder and inherited intellectual disabilities. The study opens in new tab/window in The Journal of Molecular Diagnostics opens in new tab/window, published by Elsevier, addresses the urgent need for a screening tool to identify carriers of FXS in a more comprehensive, faster, efficient, and cost-effective way compared to current methods, for better informed genetic counseling.

FXS affects approximately 1 in 7000 females and 1 in 4000 males worldwide. Common characteristics include mild to severe intellectual disability, developmental delays in speech and motor skills, behavioral and social issues such as ADHD-like and autism spectrum disorder symptoms, sensory sensitivities, and sometimes characteristic physical features.

Lead investigator Qiwei Guo, PhD, Department of Central Laboratory, Department of Obstetrics and Gynecology, Fujian Key Clinical Specialty of Laboratory Medicine, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China, says, “Although FXS carrier prevalence is high, with all major ethnic groups and races being susceptible to FXS, widespread FXS carrier screening for the general population has remained debatable. Based on previous research, clinical interest has shifted from ‘whether to perform’ to ‘how to perform’ population-based FXS carrier screening. However, an accurate, fast, affordable, and effective carrier screening assay that can examine a large number of female samples was still lacking. In this study, we developed a reliable and user-friendly software to analyze sequencing data and report results.”

The gene responsible for FXS is fragile X messenger ribonucleoprotein1 (FMR1), an X-linked dominant gene with full penetrance in all males and many females. It plays a crucial role in synapse formation and normal dendrite development. The number of CGG repeats, a specific sequence of DNA building blocks, is a key indicator of whether someone has a normal FMR1 gene, carries a premutation, or has the full mutation that causes FXS.

Co-investigator Yulin Zhou, PhD, Department of Central Laboratory, Department of Obstetrics and Gynecology, Fujian Key Clinical Specialty of Laboratory Medicine, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, China, explains, “We demonstrated that the nanopore sequencing assay can accurately identify the full range of premutation FMR1 alleles, which account for the majority of FXS carriers, and the nanopore sequencing assay was able to reliably quantify CGG repeats and AGG interruptions, two specific DNA sequence variations that are critical for determining the risk of full mutation expansion in carriers, thus facilitating genetic counseling for carrier screening.”

By utilizing identifier sequences, the researchers were able to test multiple samples in a single assay, dramatically increasing test capacity and reducing costs. The nanopore sequencing assay can be accomplished within a short turnaround time (approximately two days for an assay testing 100 simultaneously) by a technician in a standard molecular diagnostics laboratory. Compared to other commonly used techniques, the equipment for nanopore sequencing assays is more accessible and portable, and thus could be more readily and widely adapted, particularly in underdeveloped regions of the world.

Dr. Guo concludes, “We focus on controlling human genetic diseases and reducing birth defects. Given the significant morbidity associated with FXS and the lack of effective treatments, prenatal diagnosis and intervention are warranted. Our findings demonstrate that this novel nanopore sequencing assay overcomes key limitations of existing methods for FXS carrier screening, ultimately paving the way for enhanced genetic counseling and broader implementation worldwide.”

Notes for editors

The article is “Fragile X Syndrome Carrier Screening Using a Nanopore Sequencing Assay,” by Zhongmin Xia, Qiuxiao Deng, Ping Hu, Chunliu Gao, Yu Jiang, Yulin Zhou, and Qiwei Guo (https://doi.org/10.1016/j.jmoldx.2025.03.008 opens in new tab/window). The article appears online ahead of The Journal of Molecular Diagnostics, volume 27, issue 7 (July 2025), published by Elsevier.

The article is openly available for 30 days at https://www.jmdjournal.org/article/S1525-1578(25)00090-X/fulltext opens in new tab/window.

Full text of this article and additional information are also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected] opens in new tab/window. Journalists wishing to interview the study authors should contact Qiwei Guo, PhD, at [email protected] opens in new tab/window.

About The Journal of Molecular Diagnostics

The Journal of Molecular Diagnostics opens in new tab/window, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition. www.jmdjournal.org opens in new tab/window

About Elsevier

A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.